FDA Approves Edwards' Sapien 3 TAVR System Earlier Than Expected
This article was originally published in The Gray Sheet
Executive Summary
The third-generation transcatheter aortic valve has been available in Europe for over a year, will have a long head-start on rival Medtronic's next generation TAVR, Evolut R, in the U.S. market.